The acquisition occured for about $52m in cash and future contingent payments would total up to nearly $6m.
The assets include cGMP manufacturing sites designed for regulated markets, two completed and operational plants and three under construction.
The first operational plant manufactures general injectables while the second operational plant manufactures Cephalosporins in various forms such as oral liquids & solids as well as dry syrups and dry powder injectables
The three plants under construction are expected to be operational in 2012 and will develop Carbapenems, Hormonal and Oncology related injectables.